These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
435 related articles for article (PubMed ID: 24205730)
1. [Statin therapy for atherogenic hypertriglyceridemia]. Koba S Nihon Rinsho; 2013 Sep; 71(9):1655-60. PubMed ID: 24205730 [TBL] [Abstract][Full Text] [Related]
2. Effects of increasing doses of atorvastatin on the atherogenic lipid subclasses commonly associated with hypertriglyceridemia. Karalis DG; Ishisaka DY; Luo D; Ntanios F; Wun CC Am J Cardiol; 2007 Aug; 100(3):445-9. PubMed ID: 17659926 [TBL] [Abstract][Full Text] [Related]
3. Hypertriglyceridemia: a review of clinical relevance and treatment options: focus on cerivastatin. Breuer HW Curr Med Res Opin; 2001; 17(1):60-73. PubMed ID: 11464448 [TBL] [Abstract][Full Text] [Related]
4. Cholesterol efflux and metabolic abnormalities associated with low high-density-lipoprotein-cholesterol and high triglycerides in statin-treated coronary men with low-density lipoprotein-cholesterol <70 mg/dl. Posadas-Sánchez R; Posadas-Romero C; Mendoza-Pérez E; Caracas-Portilla NA; Cardoso-Saldaña G; Medina-Urrutia A; Jorge-Galarza E; Juárez-Rojas JG Am J Cardiol; 2012 Mar; 109(5):636-41. PubMed ID: 22169129 [TBL] [Abstract][Full Text] [Related]
5. Are all statins the same? Focus on the efficacy and tolerability of pitavastatin. da Silva PM Am J Cardiovasc Drugs; 2011; 11(2):93-107. PubMed ID: 21446776 [TBL] [Abstract][Full Text] [Related]
6. Hypertriglyceridemia and residual dyslipidemia in statin-treated, patients with diabetes at the highest risk for cardiovascular disease and achieving very-low low-density lipoprotein-cholesterol levels. Querton L; Buysschaert M; Hermans MP J Clin Lipidol; 2012; 6(5):434-42. PubMed ID: 23009779 [TBL] [Abstract][Full Text] [Related]
7. A VOYAGER Meta-Analysis of the Impact of Statin Therapy on Low-Density Lipoprotein Cholesterol and Triglyceride Levels in Patients With Hypertriglyceridemia. Karlson BW; Palmer MK; Nicholls SJ; Lundman P; Barter PJ Am J Cardiol; 2016 May; 117(9):1444-8. PubMed ID: 26969416 [TBL] [Abstract][Full Text] [Related]
8. [Diabetic dyslipidaemia and the atherosclerosis]. Márk L; Dani G Orv Hetil; 2016 May; 157(19):746-52. PubMed ID: 27133274 [TBL] [Abstract][Full Text] [Related]
9. Meta-analysis of comparative efficacy of increasing dose of Atorvastatin versus Rosuvastatin versus Simvastatin on lowering levels of atherogenic lipids (from VOYAGER). Nicholls SJ; Brandrup-Wognsen G; Palmer M; Barter PJ Am J Cardiol; 2010 Jan; 105(1):69-76. PubMed ID: 20102893 [TBL] [Abstract][Full Text] [Related]
10. Long-chain omega-3 fatty acids, fibrates and niacin as therapeutic options in the treatment of hypertriglyceridemia: a review of the literature. Ito MK Atherosclerosis; 2015 Oct; 242(2):647-56. PubMed ID: 26296750 [TBL] [Abstract][Full Text] [Related]
11. High-dose statin therapy with rosuvastatin reduces small dense LDL and MDA-LDL: The Standard versus high-dose therApy with Rosuvastatin for lipiD lowering (SARD) trial. Nishikido T; Oyama J; Keida T; Ohira H; Node K J Cardiol; 2016 Apr; 67(4):340-6. PubMed ID: 26162946 [TBL] [Abstract][Full Text] [Related]
12. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study. Strandberg TE; Feely J; Sigurdsson EL; Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694 [TBL] [Abstract][Full Text] [Related]
13. Fasting triglycerides predict recurrent ischemic events in patients with acute coronary syndrome treated with statins. Schwartz GG; Abt M; Bao W; DeMicco D; Kallend D; Miller M; Mundl H; Olsson AG J Am Coll Cardiol; 2015 Jun; 65(21):2267-75. PubMed ID: 26022813 [TBL] [Abstract][Full Text] [Related]
14. Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomes. Abdel-Maksoud M; Sazonov V; Gutkin SW; Hokanson JE J Cardiovasc Pharmacol; 2008 Apr; 51(4):331-51. PubMed ID: 18427276 [TBL] [Abstract][Full Text] [Related]
15. The DISCOVERY PENTA study: a DIrect Statin COmparison of LDL-C Value--an Evaluation of Rosuvastatin therapY compared with atorvastatin. Fonseca FA; Ruiz A; Cardona-Muñoz EG; Silva JM; Fuenmayor N; Marotti M; Curr Med Res Opin; 2005 Aug; 21(8):1307-15. PubMed ID: 16083541 [TBL] [Abstract][Full Text] [Related]
16. Alteration of relation of atherogenic lipoprotein cholesterol to apolipoprotein B by intensive statin therapy in patients with acute coronary syndrome (from the Limiting UNdertreatment of lipids in ACS With Rosuvastatin [LUNAR] Trial). Ballantyne CM; Pitt B; Loscalzo J; Cain VA; Raichlen JS Am J Cardiol; 2013 Feb; 111(4):506-9. PubMed ID: 23237107 [TBL] [Abstract][Full Text] [Related]
17. Statins and LDL-cholesterol lowering: an overview. Stroes E Curr Med Res Opin; 2005; 21 Suppl 6():S9-16. PubMed ID: 16138936 [TBL] [Abstract][Full Text] [Related]
18. Non-high-density lipoprotein cholesterol: a target of lipid-lowering in dialysis patients. Wanner C; Krane V Am J Kidney Dis; 2003 Mar; 41(3 Suppl 1):S72-5. PubMed ID: 12612957 [TBL] [Abstract][Full Text] [Related]
19. Hypertriglyceridemia as a possible independent risk factor for stroke. Lisak M; Demarin V; Trkanjec Z; Basić-Kes V Acta Clin Croat; 2013 Dec; 52(4):458-63. PubMed ID: 24696996 [TBL] [Abstract][Full Text] [Related]
20. Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome. Grundy SM Am J Cardiol; 1998 Feb; 81(4A):18B-25B. PubMed ID: 9526809 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]